These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 21257324)
1. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Werhahn KJ; Klimpe S; Balkaya S; Trinka E; Krämer G Seizure; 2011 May; 20(4):305-11. PubMed ID: 21257324 [TBL] [Abstract][Full Text] [Related]
2. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Heo K; Lee BI; Yi SD; Huh K; Kim JM; Lee SA; Shin DJ; Song HK; Lee SK; Kim JY; Lu S; Dubois C; Tonner F Seizure; 2007 Jul; 16(5):402-9. PubMed ID: 17369059 [TBL] [Abstract][Full Text] [Related]
4. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials. Uthman BM; Almas M; Emir B; Giordano S; Leon T Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392 [TBL] [Abstract][Full Text] [Related]
5. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
6. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011 [TBL] [Abstract][Full Text] [Related]
7. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573 [TBL] [Abstract][Full Text] [Related]
8. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy. Tanaka S; Tanaka T Epileptic Disord; 2013 Jun; 15(2):132-41. PubMed ID: 23774199 [TBL] [Abstract][Full Text] [Related]
9. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Steinhoff BJ; Trinka E; Wieser HG; Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256 [TBL] [Abstract][Full Text] [Related]
10. Levetiracetam in refractory epilepsy: a prospective observational study. Mohanraj R; Parker PG; Stephen LJ; Brodie MJ Seizure; 2005 Jan; 14(1):23-7. PubMed ID: 15642496 [TBL] [Abstract][Full Text] [Related]
11. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Abou-Khalil B; Hemdal P; Privitera MD Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083 [TBL] [Abstract][Full Text] [Related]
13. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175 [TBL] [Abstract][Full Text] [Related]
14. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Peake D; Mordekar S; Gosalakkal J; Mukhtyar B; Buch S; Crane J; Wheway R; Rittey C; Donnelly J; Whitehouse WP; Philip S Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474 [TBL] [Abstract][Full Text] [Related]
15. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Delanty N; Jones J; Tonner F Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371 [TBL] [Abstract][Full Text] [Related]
16. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Kinirons P; McCarthy M; Doherty CP; Delanty N Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211 [TBL] [Abstract][Full Text] [Related]
17. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study. Chung S; Ceja H; Gawłowicz J; McShea C; Schiemann J; Lu S Epilepsy Res; 2016 Feb; 120():7-12. PubMed ID: 26716580 [TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of levetiracetam for partial seizures. Abou-Khalil B; Schaich L Seizure; 2005 Dec; 14(8):577-85. PubMed ID: 16280250 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Perry MS; Benatar M Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of levetiracetam in clinical practice: results of the SKATE trial from Belgium and The Netherlands. Lambrechts DA; Sadzot B; van Paesschen W; van Leusden JA; Carpay J; Bourgeois P; Urbain E; Boon PA Seizure; 2006 Sep; 15(6):434-42. PubMed ID: 16893660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]